Search results: (10000)
News New Alternative in the Treatment of Diffuse Large B-cell Lymphoma
For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not suitable candidates for autologous stem cell transplantation, a wide range of treatment regimens is available. Recently, the addition of polatuzumab vedotin to rituximab and bendamustine therapy has shown promising efficacy in both registration studies and real-world clinical practice.
News Targeted Therapy for DLBCL Patients Who Cannot Undergo Bone Marrow Transplant
An international team of hemato-oncologists has been involved in testing polatuzumab vedotin in patients with diffuse large B-cell lymphoma (DLBCL) who have an unfavorable prognosis. In an article published at the beginning of 2020 in the Journal of Clinical Oncology, they analyze data collected in the early phases of clinical evaluation.
News Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS
Ozanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It is approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and moderate to severe ulcerative colitis (UC) and continues to undergo intensive clinical research. The DAYBREAK open-label, single-arm study for participants with RRMS from previous trials with ozanimod was scheduled to be completed by January 2023, and its final results can therefore be expected soon. The following article presents the interim analysis results of this study 5 years after initiation.
News Von Willebrand Disease in Women
Even in the context of gynecological issues, it is sometimes necessary to consider a hematological etiology of difficulties. The recommendations of the American College of Obstetricians and Gynecologists (ACOG) in this context focus on the possible connections with von Willebrand disease.
News Role of Chemoimmunotherapy in the Era of Rapid Development of CLL Treatment Strategies and Emergence of New Drugs
In the context of the significant advancements in the field of immunotherapy and evidence of its efficacy in the treatment of chronic lymphocytic leukemia, it is pertinent to ask how this will influence therapeutic strategies in the context of first-line treatment and what the role of chemoimmunotherapy will be in the algorithms for CLL. At the 2019 NCCN Annual Congress, a panel of experts, led by Professors William G. Wierda from Texas MD Anderson Cancer Center and Jennifer R. Brown from Dana-Farber Cancer Institute, debated this topic.
News Experiences with treating PBC with obeticholic acid in Brno's CKTCH
MUDr. Libuše Husová, Ph.D., shared the current insights from the therapy of patients with primary biliary cholangitis (PBC) using obeticholic acid (OCA) gained at the Center for Cardiovascular and Transplantation Surgery in Brno (CKTCH) during the XLVIII May Hepatology Days.
News Residual Pulmonary Hypertension After Endarterectomy: How Common Is It?
Pulmonary endarterectomy is the only potentially curative option in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH). What are its outcomes and in what percentage of cases does it lead to complete cure? A meta-analysis, significantly contributed to by Czech experts, was dedicated to the improvement of signs and symptoms of CTEPH after performing endarterectomy.
News Clinical Profile and Outcomes of Patients with Cardiac Amyloidosis – Spanish Experience from Real Practice
Cardiac amyloidosis is caused by the deposition of amyloid fibrils in the myocardium and is among the diseases with significant diagnostic delay. Physicians from the University Hospital in Madrid shared their experiences with the diagnosis and treatment of these patients over the last decade in the cited work below.
News Can Thyroid Hormone Supplementation Reduce the Risk of Cognitive Disorders?
The recent systematic literature review presented below, published by authors from the California Institute of Behavioral Neurosciences and Psychology (CIBNP), focused, among other things, on potential associations between hypothyroidism and dementia and the impact of related therapeutic interventions in terms of improving cognitive functions.
News Impact of Sacubitril/Valsartan Treatment on Left Ventricular Reverse Remodeling
A meta-analysis evaluated the effect of sacubitril/valsartan on echocardiographic parameters (not only) in patients with HFrEF. The authors focused on both the presence and significance of changes, as well as the speed of their onset after the initiation of treatment.
News How to Dose Beta-Blockers After Myocardial Infarction?
In patients after myocardial infarction (MI), there is a frequent administration of too low doses of beta-blockers (BB) and rare upward titration of their dose after discharge from the hospital. The SWEDEHEART study investigated to what extent the BB dose actually affects 5-year cardiovascular (CV) outcomes, and data from the American registry allowed a focus on mortality after MI depending on BB dosing.
News Care for Dental Prostheses: What Did Clinical Study Results Reveal?
Dental prostheses are one of the most common solutions for missing teeth, especially in the elderly population. It is estimated that by 2050 up to 2 billion people will be aged 60 or older. Currently, it's not even half that, so it's likely that the number of people with dental prostheses will continue to increase. What do current research findings on dental prosthesis care reveal, and which cleaning methods have been evaluated as truly effective?
News Temporary Interruption of Treatment or Dose Modification of Ibrutinib in CLL Patients
A team from the Mayo Clinic in Rochester, USA, published a study this March in the journal Cancer Medicine, focusing on aspects of ibrutinib therapy in real clinical practice. The authors evaluated the impact of dose modification or temporary interruption of the drug administration.
News Orally Administered Berotralstat in the Prevention of Hereditary Angioedema Attacks
Berotralstat is an oral medication administered once daily, developed to prevent hereditary angioedema (HAE) attacks. It is a kallikrein protease inhibitor, which plays a key role in the pathogenesis of this disease. A phase III clinical trial, with results recently published in the Journal of Allergy and Clinical Immunology, evaluated the efficacy and safety of two dosing regimens of berotralstat compared to placebo in patients with HAE.
News Comparison of EHL Products in the Treatment of Hemophilia A – Pharmacoeconomic Analysis
In the work presented below, whose results were recently published, a model combining pharmacokinetic and pharmacodynamic data was developed. With its help, the authors tried to compare the bleeding rates in hemophiliacs treated with various EHL products. At the same time, they focused on the cost-effectiveness of this treatment.
News Position of Generic Drugs in Oncology: What Are Their Main Advantages?
Generics – as is well known – are products containing the same active substance as the original medicinal product, which can enter the market after the patent protection of the original drug has expired. They are applied in various medical fields, including oncology. The main goal of producing generics is to improve the accessibility of treatment for a wide range of patients while maintaining the safety and effectiveness of the therapy.
News 6 Possible Benefits of Adding Empagliflozin to Metformin
Currently, there is intense discussion about the advantages of sodium-glucose co-transporter 2 inhibitors (SGLT2i, also known as gliflozins) in terms of their cardio and nephroprotective properties. Below, we summarize the proven beneficial effects specifically associated with adding empagliflozin to metformin and mention the indications for empagliflozin, which are reimbursed.
News Efficacy and Safety of Soybean and Avocado Unsaponifiables in the Treatment of Knee and Hip Osteoarthritis
Osteoarthritis represents a chronic irreversible degenerative joint disease, the prevalence of which increases with age. Various approaches are applied in therapy, including the administration of preparations aimed at reducing symptoms of the disease and slowing its progression. A recently published study provides current insights into the efficacy and safety of unsaponifiable soybean and avocado oil in the treatment of hip and knee osteoarthritis.